CSIMarket
 
Benitec Biopharma Inc   (NASDAQ: BNTC)
Other Ticker:  
 
 
Price: $14.6100 $-0.33 -2.209%
Day's High: $15.46 Week Perf: -8.23 %
Day's Low: $ 14.16 30 Day Perf: 7.43 %
Volume (M): 183 52 Wk High: $ 17.15
Volume (M$): $ 2,666 52 Wk Avg: $11.27
Open: $15.00 52 Wk Low: $6.66



 Market Capitalization (Millions $) 564
 Shares Outstanding (Millions) 39
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) 89
 Capital Exp. (TTM) (Millions $) 0

Benitec Biopharma Inc
Benitec Biopharma Inc is a biotechnology company headquartered in California, USA. The company specializes in the development of gene therapy treatments for various diseases using its patented gene-silencing technology called DNA-directed RNA interference (ddRNAi). This technology allows for the suppression or elimination of specific genes associated with diseases, offering a potential cure or treatment.

Benitec Biopharma has a diverse pipeline of therapeutic candidates targeting diseases such as hepatitis B, head and neck squamous cell carcinoma, and ocular diseases. The company's lead product candidate, BB-301, is being developed as a potentially curative treatment for oculopharyngeal muscular dystrophy (OPMD), a rare genetic disease.

The company's approach focuses on creating long-lasting and potentially permanent gene expression changes, providing durable treatment options for patients. In addition to its internal pipeline, Benitec Biopharma also collaborates with research institutions and pharmaceutical companies to further develop and commercialize its gene therapy platform.

Overall, Benitec Biopharma Inc is committed to advancing the field of gene therapy and providing innovative treatments for various diseases using their proprietary ddRNAi technology.


   Company Address: 3940 Trust Way Hayward 94545 CA
   Company Phone Number: 780-0819   Stock Exchange / Ticker: NASDAQ BNTC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        0.56% 
PFE   -2.32%    
REGN   -3.69%    
SRPT   -44.5%    
UTHR        2.61% 
VRTX   -3.2%    
• View Complete Report
   



Shares

Benitec Biopharma Rises: Evaluating the Impact of a $30 Million Equity Offering on Shares

Published Tue, Mar 25 2025 12:01 PM UTC

Benitec Biopharma Inc. Announces $30 Million Common Stock OfferingOn March 25, 2025, Benitec Biopharma Inc. (Nasdaq: BNTC) announced a significant move in its financing strategy, revealing the pricing of a combined $30 million offering of common stock. The clinical-stage biotechnology company, known for its innovative gene therapy solutions based on the proprietary DNA-direc...

Clinical Study

Benitec Biopharma Inc. has recently reported promising results from its Phase 1b/2a clinical study of BB-30...

Published Sat, Oct 12 2024 10:30 AM UTC

Positive Clinical Outcomes for Benitec Biopharma?s BB-301 in Phase 1b/2a Study Amidst Market Performance Struggles Benitec Biopharma Inc. has recently reported promising results from its Phase 1b/2a clinical study of BB-301, a gene therapy aimed at treating patients with swallowing disorders. The data was presented at the 29th Annual Congress of the World Muscle Society and ...

Clinical Study

Advances in Gene Therapy Insights from Benitec Biopharmas BB-301 Phase 1b/2a Study and Industry Context

Published Wed, Sep 18 2024 12:00 PM UTC

: Gene therapy has emerged as a promising frontier in the treatment of genetic disorders, with innovative approaches such as RNA interference gaining traction. This article discusses the latest developments from Benitec Biopharma s BB-301 clinical study concerning Oculopharyngeal Muscular Dystrophy (OPMD), as presented at the 29th Annual Congress of the World Muscle Societ...

Clinical Study

Unleashing the Power of Gene Therapy BB-301 Shows Promise in OPMD TreatmentNote has been revised ...

Published Mon, Jul 15 2024 10:00 AM UTC

: Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, inherited disorder that predominantly affects the muscles involved in swallowing. Benitec Biopharma, a renowned biotechnology company, has reported promising results from their Phase 1b/2a clinical trial assessing the safety and efficacy of gene therapy candidate BB-301 as a potential treatment for OPMD. This article aim...

Benitec Biopharma Inc

Benitec Biopharma Inc Struggles to Generate Revenue in Q3 2024, What's Next for the Major Pharmaceutical Player?



In a groundbreaking development, Australian-based biopharmaceutical company Benitec Biopharma announced positive interim results from their Phase 1b/2a clinical trial for BB-301. This gene therapy holds immense potential in treating Oculopharyngeal Muscular Dystrophy (OPMD), a rare muscle disorder affecting thousands of patients worldwide. These encouraging results have the potential to significantly impact not only the lives of OPMD patients but also Benitec Biopharma's future financial performance.
Understanding OPMD and its Current Treatment Options:
Oculopharyngeal Muscular Dystrophy (OPMD) is a progressive muscle weakness disorder primarily affecting the upper eyelids and throat. This debilitating disease leads to difficulties in swallowing (dysphagia), which can result in malnutrition and aspiration pneumonia, severely impacting the quality of life for patients. Currently, treatment options for OPMD are limited to palliative care and corrective treatments, with no available disease-modifying therapies.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com